Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Apimeds Pharmaceuticals US, Inc. ( (APUS) ) is now available.
On October 15, 2025, Apimeds Pharmaceuticals US, Inc. amended its bylaws to permit shareholder action by written consent. This change could impact the company’s governance and shareholder engagement by streamlining decision-making processes.
More about Apimeds Pharmaceuticals US, Inc.
Average Trading Volume: 127,971
Technical Sentiment Signal: Strong Buy
For detailed information about APUS stock, go to TipRanks’ Stock Analysis page.